This company has been acquired
Tyme Technologies Past Earnings Performance
Past criteria checks 0/6
Key information
-6.9%
Earnings growth rate
5.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -32.6% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05TYME stock surges on merger agreement and Syros Pharmaceuticals
Jul 05Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Mar 19Tyme Technologies Offers Incredible Risk-Reward
Dec 07Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Nov 19Tyme Technologies: The Market Missed The Bullish Memo
Aug 27We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate
Jul 19Tyme Technologies reports FY results
Jun 10Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount
May 29Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Mar 26Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?
Feb 19Tyme falls after equity offer as quarterly data indicate liquidity pressure
Feb 04Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections
Feb 03Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Feb 02Revisiting Tyme Technologies
Dec 17Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?
Dec 16Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?
Dec 09Tyme Technologies names new finance chief
Nov 30Revenue & Expenses BreakdownBeta
How Tyme Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 0 | -24 | 12 | 11 |
31 Mar 22 | 0 | -24 | 10 | 13 |
31 Dec 21 | 0 | -24 | 10 | 15 |
30 Sep 21 | 0 | -25 | 9 | 15 |
30 Jun 21 | 0 | -26 | 10 | 16 |
31 Mar 21 | 0 | -29 | 10 | 17 |
31 Dec 20 | 0 | -28 | 11 | 17 |
30 Sep 20 | 0 | -28 | 12 | 16 |
30 Jun 20 | 0 | -28 | 12 | 15 |
31 Mar 20 | 0 | -22 | 13 | 13 |
31 Dec 19 | 0 | -27 | 13 | 13 |
30 Sep 19 | 0 | -29 | 14 | 14 |
30 Jun 19 | 0 | -29 | 14 | 14 |
31 Mar 19 | 0 | -33 | 15 | 15 |
31 Dec 18 | 0 | -27 | 14 | 13 |
30 Sep 18 | 0 | -25 | 13 | 11 |
30 Jun 18 | 0 | -23 | 12 | 11 |
31 Mar 18 | 0 | -19 | 11 | 9 |
31 Dec 17 | 0 | -17 | 9 | 8 |
30 Sep 17 | 0 | -14 | 7 | 7 |
30 Jun 17 | 0 | -12 | 7 | 6 |
31 Mar 17 | 0 | -15 | 9 | 6 |
31 Dec 16 | 0 | -17 | 8 | 4 |
30 Jun 16 | 0 | -13 | 9 | 5 |
31 Mar 16 | 0 | -11 | 8 | 3 |
31 Dec 15 | 0 | -12 | 4 | 4 |
Quality Earnings: TYME is currently unprofitable.
Growing Profit Margin: TYME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: TYME has a negative Return on Equity (-32.63%), as it is currently unprofitable.